| Accounting for preference heterogeneity in discrete-choice experiments: an ISPOR special interest group report C Vass, M Boeri, S Karim, D Marshall, B Craig, KA Ho, D Mott, ... Value in Health 25 (5), 685-694, 2022 | 82 | 2022 |
| Valuing EQ-5D-Y-3L health states using a discrete choice experiment: do adult and adolescent preferences differ? DJ Mott, KK Shah, JM Ramos-Goñi, NJ Devlin, O Rivero-Arias Medical Decision Making 41 (5), 584-596, 2021 | 69 | 2021 |
| Incorporating quantitative patient preference data into healthcare decision making processes: is HTA falling behind? DJ Mott The Patient-Patient-Centered Outcomes Research 11 (3), 249-252, 2018 | 64* | 2018 |
| EQ-5D-Y Value Set for Germany S Kreimeier, D Mott, K Ludwig, W Greiner, IHTAH Group PharmacoEconomics, 2022 | 50* | 2022 |
| Considering severity in health technology assessment: can we do better? C Skedgel, N Henderson, A Towse, D Mott, C Green Value in Health 25 (8), 1399-1403, 2022 | 37 | 2022 |
| Criteria for developing, assessing and selecting candidate EQ-5D bolt-ons BJ Mulhern, C Sampson, P Haywood, R Addo, K Page, D Mott, K Shah, ... Quality of Life Research 31 (10), 3041-3048, 2022 | 31 | 2022 |
| Reporting quality of marginal rates of substitution in discrete choice experiments that elicit patient preferences DJ Mott, N Chami, T Tervonen Value in Health 23 (8), 979-984, 2020 | 30 | 2020 |
| Does changing the age of a child to be considered in 3-level version of EQ-5D-Y discrete choice experiment–based valuation studies affect health preferences? JM Ramos-Goñi, A Estévez-Carrillo, O Rivero-Arias, D Rowen, D Mott, ... Value in Health 25 (7), 1196-1204, 2022 | 27 | 2022 |
| Whose preferences should be elicited for use in health-care decision-making? A case study using anticoagulant therapy DJ Mott, M Najafzadeh Expert Review of Pharmacoeconomics & Outcomes Research 16 (1), 33-39, 2016 | 23 | 2016 |
| Resource allocation in public sector programmes: does the value of a life differ between governmental departments? P Cubi-Molla, D Mott, N Henderson, B Zamora, M Grobler, M Garau Cost Effectiveness and Resource Allocation 21 (1), 96, 2023 | 18 | 2023 |
| A European, prospective, observational study of enzalutamide in patients with metastatic castration-resistant prostate cancer: PREMISE H Payne, A Robinson, B Rappe, S Hilman, U De Giorgi, S Joniau, ... International Journal of Cancer, 2021 | 17 | 2021 |
| Modelling spillover effects on informal carers: the carer QALY trap DJ Mott, H Schirrmacher, H Al-Janabi, S Guest, B Pennington, N Scheuer, ... Pharmacoeconomics 41 (12), 1557-1561, 2023 | 15 | 2023 |
| Analytical considerations when anchoring discrete choice experiment values using composite time trade-off data: the case of EQ-5D-Y-3L DJ Mott, NJ Devlin, S Kreimeier, R Norman, KK Shah, O Rivero-Arias Pharmacoeconomics 40 (Suppl 2), 129-137, 2022 | 13 | 2022 |
| Challenges in valuing temporary health states for economic evaluation: a review of empirical applications of the chained time trade-off method J Stoniute, DJ Mott, J Shen Value in Health 21 (5), 605-611, 2018 | 13 | 2018 |
| A multinational European study of patient preferences for novel diagnostics to manage antimicrobial resistance DJ Mott, G Hampson, MJ Llewelyn, J Mestre-Ferrandiz, MM Hopkins Applied Health Economics and Health Policy 18 (1), 69-79, 2020 | 12 | 2020 |
| Conducting a time trade-off study alongside a clinical trial: a case study and recommendations J Shen, S Hill, D Mott, M Breckons, L Vale, R Pickard PharmacoEconomics-open 3 (1), 5-20, 2019 | 10 | 2019 |
| Do preferences differ based on respondent experience of a health issue and its treatment? A case study using a public health intervention. DJ Mott, L Ternent, L Vale European Journal of Health Economics 24 (3), 2023 | 8 | 2023 |
| Public preferences for health gains and cures: a discrete choice experiment G Hampson, D Mott, N Devlin, K Shah Office of Health Economics, 2019 | 5 | 2019 |
| Estimating latent scale discrete choice utilities to develop an EQ-5D-Y value set in the UK O Rivero-Arias, KK Shah, JM Ramos-Goñi, D Mott, N Develin EuroQoL Plenary, 2017 | 5 | 2017 |
| Patient Preferences for Treatment in Relapsed/Refractory Acute Leukemia in the United Kingdom: A Discrete Choice Experiment DJ Mott, J Hitch, S Nier, Z Pemberton-Whiteley, C Skedgel Patient preference and adherence, 1243-1255, 2024 | 4 | 2024 |
Koonal ShahNational Institute for Health and Care Excellence; University of SheffieldVerified email at nice.org.uk
